Crossmark

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience

Crossref DOI link: https://doi.org/10.1007/s00277-018-3328-3

Published Online: 2018-04-16

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ciochetto, Chiara https://orcid.org/0000-0002-9415-4208
Botto, Barbara

Passera, Roberto

Bellò, Marilena

Benevolo, Giulia

Boccomini, Carola

Castellino, Alessia

Chiappella, Annalisa

Freilone, Roberto

Nicolosi, Maura

Orsucci, Lorella

Pecoraro, Clara

Pregno, Patrizia

Bisi, Gianni

Vitolo, Umberto
License Information

Text and Data Mining valid from 2018-04-16
More Information

Article History

Received: 3 November 2017

Accepted: 4 April 2018

First Online: 16 April 2018

Compliance with ethical standards

:

: Umberto Vitolo was on the advisory committee of Roche, Janssen and received a lecture fee from Roche, Celgene, Janssen, Takeda, and Gilead.The remaining authors declare no competing financial interests.

Document is current

Any future updates will be listed below